Advanced Biomed Inc.

Advanced Biomed Inc. is a Nevada-incorporated holding company operating through two main subsidiaries: Advanced Biomed Taiwan and Advanced Biomed HK. Advanced Biomed Taiwan handles the company's primary operations, including the design and development of core technologies and products. Since its establishment in 2014, the company has focused on integrating interdisciplinary technologies, developing a microfluidic technology platform. This platform leverages the physical and molecular biological characteristics of tumor cells, combining semiconductor technology and biotechnology to create complex precision structures, dielectric detection, functional microfluidic biochips, microfluidic integrated semiconductor sensors, related application modules, and key components for medical testing equipment. The company also develops medical testing equipment and related products by integrating microfluidic modules, automation software, and hardware. These technologies and products are designed for early screening and detection, diagnosis and staging, and cancer treatment through the detection of circulating tumor cells and related tumor markers in blood samples, capture of single circulating tumor cells, and single-cell sorting and determination. They aim to assist in treatment selection and patient prognosis intervention upon obtaining necessary licenses and approvals. Advanced Biotech HK is responsible for market operations and management in China, localized production, product registration, and future local market sales in accordance with local regulations. The Shanghai subsidiary holds R&D equipment and patents and will manage clinical trials in Mainland China via CROs. The company plans to establish future operation centers in North America and Europe. Key devices include A + Pre, AC-1000, A + CellScan, and A + SCDrop, along with three microfluidic biochips: A + Pre Chip, AC-1000 CTC Enrichment Chip, and A + CellScan Chip, all designed to offer rapid and affordable assay products and services to cancer patients.